Clarient has launched a new gene mutation test to help physicians select the appropriate therapy for non-small cell lung cancer.
VIVUS’ Qnexa Shows Promise For Diabetics
VIVUS, a pharmaceutical company specializing in products to treat sexual function, announced that their experimental obesity drug Qnexa was shown to improve blood sugar control in patients with type 2 diabetes.
Electro-Optical Submits MelaFind for Premarket Approval
Electro-Optical Sciences anounced that it has submitted a Premarket Approval Application to the U.S. Food and Drug Administration for MelaFind.
Burrill Report: Financing Activity May Lift Cloud Hanging Over Biotech Industry
While biotech leaders from all over the world gathered at the 2009 BIO International Convention in Atlanta, financing activity in the sector raised hope that the cloud hanging over the industry may be lifting a little.
Biogen Idec, Electro-Optical Among “5 Stocks Approaching Greatness”
Investment website The Motley Fool has published a list of five stocks approaching greatness–and four of them are within the life sciences industry.
Clarient Stock Deal Frees Up Cash for Safeguard Scientifics
Safeguard Scientifics Inc. has received $19.5 million in cash, and freed up another $12.3 million in cash due to one of its portfolio companies completing the second part of a private placement of convertible preferred stock.
TargetScan Touch Proven Effective in Duke Study
A study published in Technology in Cancer Research and Treatment shows that Envisioneering Medical’s TargetScan Touch system is more effective in detecting prostate cancer than traditional biopsy methods.
New Orleans to Promote City’s Bio-Boom
The New Orleans BioInnovation Center is embarking on a new campaign to lure bio industry workers back to the city.
